P. Kazanjian, UNAIDS 90-90-90 Campaign to End the AIDS Epidemic in Historic Perspective, The Milbank Quarterly, vol.95, issue.2, pp.408-439, 2017.

|. Who-europe and . Hiv/, submission-from-international-hivaids-alliance-in-ukraine-canadian-hivaids-legal-network-eurasian-harm-reduction-network1, AIDS [Internet]

S. Matheron, SIDA : actualités, Médecine et Maladies Infectieuses, vol.26, issue.1, pp.3-10, 1996.

J. Ghosn, Vaccinations Classiques et Infection par le VIH, VIH et sida, pp.155-159, 2008.

. Haute-autorité-de-santé, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

D. K. Smith, J. H. Herbst, X. Zhang, and C. E. Rose, Condom Effectiveness for HIV Prevention by Consistency of Use Among Men Who Have Sex With Men in the United States, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.68, issue.3, pp.337-344, 2015.

W. D. Johnson, A. O?leary, and S. A. Flores, Per-partner condom effectiveness against HIV for men who have sex with men, AIDS, vol.32, issue.11, pp.1499-1505, 2018.

G. Enquete-presse, Médecins, santé et société : une enquête nationale, La Presse Médicale, vol.33, issue.22, p.1616, 2004.

A. Velter, L. Saboni, A. Bouyssou, P. Bernillon, C. Sommen et al., Echantillons de convenance par Internet et par la presse - Enquête Presse Gays et Lesbiennes 2011, Bulletin of Sociological Methodology/Bulletin de Méthodologie Sociologique, vol.126, issue.1, pp.46-66, 2015.

. Invs--bulletin-Épidémiologique-hebdomadaire, , 2018.

M. S. Cohen, Y. Q. Chen, and M. Mccauley, Prevention of HIV-1 Infection with Antiretroviral Therapy, New England Journal of Medicine, vol.365, issue.20, pp.1934-1935, 2011.

M. S. Cohen, S. Eshleman, M. Mccauley, and Y. Q. Chen, Antiretroviral Therapy to Prevent HIV Acquisition: Limits of Estimation From a Population Cohort, Clinical Infectious Diseases, vol.63, issue.12, pp.1679-1680, 2016.

S. Vaux, S. Chevaliez, L. Saboni, C. Sauvage, C. Sommen et al., Prévalence des infections par les virus des hépatites C (VHC) et B (VHB) et couverture vaccinale contre le VHB chez les hommes ayant des relations sexuelles avec des hommes fréquentant des lieux de convivialité gay de cinq villes françaises, Médecine et Maladies Infectieuses, vol.48, issue.4, p.S29, 2018.

. Invs--bulletin-Épidémiologique-hebdomadaire,

A. Rodger, V. Cambiano, and T. Bruun, Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: the PARTNER2 Study extended results in gay men, Program and abstracts of the 22nd International AIDS Conference, 2018.

B. R. Bavinton, A. N. Pinto, N. Phanuphak, B. Grinsztejn, G. P. Prestage et al., Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study, The Lancet HIV, vol.5, issue.8, pp.e438-e447, 2018.

. Insight-start-study, . Group, J. D. Lundgren, and A. G. Babiker, Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, New England Journal of Medicine, vol.373, issue.9, pp.795-807, 2015.

C. Danel and R. Moh, A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa, New England Journal of Medicine, vol.373, issue.9, pp.808-822, 2015.

D. M. Cardo, D. H. Culver, C. A. Ciesielski, P. U. Srivastava, R. Marcus et al., A Case?Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure, New England Journal of Medicine, vol.337, issue.21, pp.1485-1490, 1997.

M. Schechter, R. F. Do-lago, A. B. Mendelsohn, R. I. Moreira, L. H. Moulton et al., Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Postexposure Chemoprophylaxis for HIV, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.5, pp.519-525, 2004.

R. C. Berg, M. W. Ross, P. Weatherburn, and A. J. Schmidt, Structural and environmental factors are associated with internalised homonegativity in men who have sex with men: Findings from the European MSM Internet Survey (EMIS) in 38 countries, Social Science & Medicine, vol.78, pp.61-69, 2013.

N. Charpentier, G. Quatremère, and X. Mabire, Human Immunodeficiency Virus (HIV) Infection, HIV Pre-Exposure Prophylaxis (PrEP), HIV Occupational Post-Exposure Prophylaxis (oPEP), HIV Non-Occupational Post-Exposure Prophylaxis (nPEP), The APRN and PA?s Complete Guide to Prescribing Drug Therapy, 2019.

A. Fontaine, 28. Définir une politique de santé, planifier, programmer, évaluer, Traité de santé publique, vol.28, p.263, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02683411

R. M. Grant, J. R. Lama, and P. L. Anderson, Preexposure chemoprophylaxis for HIV prevention in men who have sex with men, N Engl J Med, vol.363, issue.27, pp.2587-2599, 2010.

J. Molina, C. Capitant, B. Spire, G. Pialoux, L. Cotte et al., On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection, New England Journal of Medicine, vol.373, issue.23, pp.2237-2246, 2015.
URL : https://hal.archives-ouvertes.fr/halshs-01429281

S. Mccormack, D. T. Dunn, M. Desai, D. I. Dolling, M. Gafos et al., Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial, The Lancet, vol.387, issue.10013, pp.53-60, 2016.

J. Molina, I. Charreau, and B. Spire, Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study, Lancet HIV, vol.4, issue.9, pp.402-410, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01963237

S. Billioti-de-gage, F. Raguideau, A. Rudnichi, and R. Dray-spira, Utilisation de la prophylaxie pré-exposition au VIH par l?association fixe emtricitabine/ténofovir (Truvada ® ou génériques) : étude longitudinale à partir des bases médico-administratives françaises, Revue d'Épidémiologie et de Santé Publique, vol.66, p.S226, 2018.

I. Durand-zaleski, P. Mutuon, I. Charreau, C. Tremblay, D. Rojas et al., Costs and benefits of on-demand HIV preexposure prophylaxis in MSM, AIDS, vol.32, issue.1, pp.95-102, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02090365

J. Bressy, Prise en charge du VIH -Recommandations du groupe d'experts

F. M. Kpoundia, L?expertise profane dans la prise en charge hospitalière du VIH/SIDA au Cameroun : entre bénévolat et emploi, Anthropologie et Santé, issue.10, 2015.

A. E. Grulich, R. Guy, and J. Amin, Questions and Answers: The iPrEx Study: Pre-Exposure Prophylaxis as HIV Prevention Among Men who Have Sex with Men, Lancet HIV, 2010.

N. Nwokolo, A. Hill, A. Mcowan, and A. Pozniak, Rapidly declining HIV infection in MSM in central London, The Lancet HIV, vol.4, issue.11, pp.e482-e483, 2017.

S. Billioti-de-gage, F. Raguideau, A. Rudnichi, and R. Dray-spira, Utilisation de la prophylaxie pré-exposition au VIH par l?association fixe emtricitabine/ténofovir (Truvada ® ou génériques) : étude longitudinale à partir des bases médico-administratives françaises, Revue d'Épidémiologie et de Santé Publique, vol.66, p.S226, 2018.

. Eacs-guidelines, , 2018.

M. S. Saag, C. A. Benson, R. T. Gandhi, J. F. Hoy, R. J. Landovitz et al., Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, JAMA, vol.320, issue.4, p.379, 2018.

J. L. Casado, Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End, AIDS Rev, vol.18, issue.2, pp.59-68, 2016.

T. Cihlar, E. S. Ho, D. C. Lin, and A. S. Mulato, HUMAN RENAL ORGANIC ANION TRANSPORTER 1 (hOAT1) AND ITS ROLE IN THE NEPHROTOXICITY OF ANTIVIRAL NUCLEOTIDE ANALOGS, Nucleosides, Nucleotides and Nucleic Acids, vol.20, issue.4-7, pp.641-648, 2001.

A. S. Ray, T. Cihlar, K. L. Robinson, L. Tong, J. E. Vela et al., Mechanism of Active Renal Tubular Efflux of Tenofovir, Antimicrobial Agents and Chemotherapy, vol.50, issue.10, pp.3297-3304, 2006.

R. Mallants, K. Van-oosterwyck, L. Van-vaeck, R. Mols, E. De-clercq et al., Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites, Xenobiotica, vol.35, issue.10-11, pp.1055-1066, 2005.

T. Imaoka, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi et al., Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir, Molecular Pharmacology, vol.71, issue.2, pp.619-627, 2006.

S. P. Pushpakom, N. J. Liptrott, S. Rodríguez-nóvoa, P. Labarga, V. Soriano et al., Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction, The Journal of Infectious Diseases, vol.204, issue.1, pp.145-153, 2011.

J. C. Yombi, A. Pozniak, M. Boffito, R. Jones, S. Khoo et al., Antiretrovirals and the kidney in current clinical practice, AIDS, vol.28, issue.5, pp.621-632, 2014.

C. Gervasoni, P. Meraviglia, S. Landonio, S. Baldelli, S. Fucile et al., Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events, PLoS ONE, vol.8, issue.12, p.e80242, 2013.

W. Lewis, B. J. Day, and W. C. Copeland, Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective, Nature Reviews Drug Discovery, vol.2, issue.10, pp.812-822, 2003.

H. Côté, A. B. Magil, and M. Harris, Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy, Antivir Ther (Lond), vol.11, issue.1, pp.79-86, 2006.

A. Karras, M. Lafaurie, A. Furco, A. Bourgarit, D. Droz et al., Tenofovir?Related Nephrotoxicity in Human Immunodeficiency Virus?Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus, Clinical Infectious Diseases, vol.36, issue.8, pp.1070-1073, 2003.

P. Penot, C. Gosset, J. Verine, and J. Molina, Tenofovir disoproxil fumarate-induced Fanconi?s syndrome during HIV postexposure prophylaxis, AIDS, vol.30, issue.8, pp.1311-1313, 2016.

D. Kim, J. Lee, D. Kim, K. Kang, S. J. Suh et al., A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B, The Korean Journal of Gastroenterology, vol.68, issue.6, p.317, 2016.

J. Lee, Bowel Preparation Formulations and Salvage Options for Inadequate Preparation, The Korean Journal of Gastroenterology, vol.68, issue.2, p.61, 2016.

S. K. Gupta, Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System, AIDS Patient Care and STDs, vol.22, issue.2, pp.99-103, 2008.

P. Labarga, P. Barreiro, L. Martin-carbonero, S. Rodriguez-novoa, C. Solera et al., Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir, AIDS, vol.23, issue.6, pp.689-696, 2009.

L. Hamzah, A. Samarawickrama, L. Campbell, M. Pope, K. Burling et al., Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients, AIDS, vol.29, issue.14, pp.1785-1792, 2015.

I. F. Grigsby, L. Pham, L. M. Mansky, R. Gopalakrishnan, A. E. Carlson et al., Tenofovir treatment of primary osteoblasts alters gene expression profiles: Implications for bone mineral density loss, Biochemical and Biophysical Research Communications, vol.394, issue.1, pp.48-53, 2010.

J. L. Casado, C. Santiuste, M. Vazquez, S. Bañón, M. Rosillo et al., Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients, AIDS, vol.30, issue.9, pp.1423-1431, 2016.

G. M. Lucas, M. J. Ross, P. G. Stock, M. G. Shlipak, C. M. Wyatt et al., Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America, Clinical Infectious Diseases, vol.59, issue.9, pp.e96-e138, 2014.

R. D. Cooper, N. Wiebe, N. Smith, P. Keiser, S. Naicker et al., Systematic Review and Meta?analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV?Infected Patients, Clinical Infectious Diseases, vol.51, issue.5, pp.496-505, 2010.

L. Ryom, A. Mocroft, and J. D. Lundgren, Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons, Current Opinion in HIV and AIDS, vol.9, issue.1, pp.41-47, 2014.

A. Mocroft, J. D. Lundgren, M. Ross, C. A. Fux, P. Reiss et al., Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study, The Lancet HIV, vol.3, issue.1, pp.e23-e32, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01908643

A. Mocroft, O. Kirk, P. Reiss, S. De-wit, D. Sedlacek et al., Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, vol.24, issue.11, pp.1667-1678, 2010.

M. Goicoechea, S. Liu, B. Best, S. Sun, S. Jain et al., Greater Tenofovir?Associated Renal Function Decline with Protease Inhibitor?Based versus Nonnucleoside Reverse?Transcriptase Inhibitor?Based Therapy, The Journal of Infectious Diseases, vol.197, issue.1, pp.102-108, 2008.

P. R. Quesada, L. L. Esteban, J. R. García, R. V. Sánchez, T. M. García et al., Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients, International Journal of Clinical Pharmacy, vol.37, issue.5, pp.865-872, 2015.

T. Nishijima, H. Gatanaga, H. Komatsu, K. Tsukada, T. Shimbo et al., Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection, PLoS ONE, vol.7, issue.1, p.e29977, 2012.

T. Nishijima, H. Komatsu, H. Gatanaga, T. Aoki, K. Watanabe et al., Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients: A Retrospective Cohort Study of Japanese Patients, PLoS ONE, vol.6, issue.7, p.e22661, 2011.

S. Jose, L. Hamzah, L. J. Campbell, T. Hill, M. Fisher et al., Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure, The Journal of Infectious Diseases, vol.210, issue.3, pp.363-373, 2014.

R. M. Grant, S. Mannheimer, J. P. Hughes, Y. Hirsch-moverman, A. Loquere et al., Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study, Clinical Infectious Diseases, vol.66, issue.11, pp.1712-1721, 2018.

M. M. Solomon, J. R. Lama, D. V. Glidden, K. Mulligan, V. Mcmahan et al., Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis, AIDS, vol.28, issue.6, pp.851-859, 2014.

K. Mugwanya, J. Baeten, C. Celum, D. Donnell, T. Nickolas et al., Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women, Journal of Infectious Diseases, vol.214, issue.7, pp.1050-1057, 2016.

K. K. Mugwanya, C. Wyatt, C. Celum, D. Donnell, N. R. Mugo et al., Changes in Glomerular Kidney Function Among HIV-1?Uninfected Men and Women Receiving Emtricitabine?Tenofovir Disoproxil Fumarate Preexposure Prophylaxis, JAMA Internal Medicine, vol.175, issue.2, p.246, 2015.

M. Martin, S. Vanichseni, P. Suntharasamai, U. Sangkum, R. Chuachoowong et al., Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand, PLoS ONE, vol.6, issue.9, p.e25127, 2011.

R. Yacoub, G. N. Nadkarni, D. Weikum, I. Konstantinidis, A. Boueilh et al., Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.71, issue.4, pp.e115-e118, 2016.

M. Gandhi, D. V. Glidden, K. Mayer, M. Schechter, S. Buchbinder et al., Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study, The Lancet HIV, vol.3, issue.11, pp.e521-e528, 2016.

V. Jotwani, R. Scherzer, D. V. Glidden, M. Mehrotra, P. Defechereux et al., Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.78, issue.2, pp.169-174, 2018.

E. C. Tang, E. Vittinghoff, P. L. Anderson, S. E. Cohen, S. Doblecki-lewis et al., Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.77, issue.2, pp.193-198, 2018.

M. Gandhi, P. M. Murnane, P. Bacchetti, R. Elion, M. A. Kolber et al., Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen, AIDS, vol.31, issue.16, pp.2245-2251, 2017.

J. L. Marcus, L. B. Hurley, C. B. Hare, D. P. Nguyen, T. Phengrasamy et al., Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.73, issue.5, pp.540-546, 2016.

K. K. Mugwanya, C. Wyatt, C. Celum, D. Donnell, J. Kiarie et al., Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.71, issue.4, pp.374-380, 2016.

K. K. Mugwanya, J. M. Baeten, C. Wyatt, N. R. Mugo, C. L. Celum et al., Brief Report, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.77, issue.2, pp.206-211, 2018.

P. E. Sax, D. Wohl, and M. T. Yin, Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials, Lancet, vol.385, issue.9987, pp.2606-2615, 2015.

E. Safety, T. Of-emtricitabine, and . Alafenamide, F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection -Full Text View -ClinicalTrials.gov, 2009.

A. Hill, S. L. Hughes, D. Gotham, and A. L. Pozniak, Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?, Journal of Virus Eradication, vol.4, issue.2, pp.72-79, 2018.

R. Gilson, Demand for Pre exposure prophylaxis for HIV (PrEP) and the impact on clinical services: Scottish men who have sex with men (MSM) perspectives., 2017.

J. M. Baeten, D. Donnell, and P. Ndase, Antiretroviral prophylaxis for HIV prevention in heterosexual men and women, N Engl J Med, vol.367, issue.5, pp.399-410, 2012.

M. C. Thigpen, P. M. Kebaabetswe, and L. A. Paxton, Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana, N Engl J Med, vol.367, issue.5, pp.423-434, 2012.

L. Van-damme, A. Corneli, K. Ahmed, K. Agot, J. Lombaard et al., Preexposure Prophylaxis for HIV Infection among African Women, New England Journal of Medicine, vol.367, issue.5, pp.411-422, 2012.

K. Choopanya, M. Martin, P. Suntharasamai, U. Sangkum, P. A. Mock et al., Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet, vol.381, issue.9883, pp.2083-2090, 2013.

J. M. Marrazzo, G. Ramjee, and B. A. Richardson, Tenofovir-based preexposure prophylaxis for HIV infection among African women, N Engl J Med, vol.372, issue.6, pp.509-518, 2015.

F. Rollot, E. Nazal, L. Chauvelot-moachon, C. Kelaidi, N. Daniel et al., Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine, Clinical Infectious Diseases, vol.37, issue.12, pp.e174-e176, 2003.

L. Ryom, A. Mocroft, and J. D. Lundgren, Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons, Current Opinion in HIV and AIDS, vol.9, issue.1, pp.41-47, 2014.

J. Fonsart, S. Saragosti, M. Taouk, G. Peytavin, L. Bushman et al., Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial, Journal of Antimicrobial Chemotherapy, vol.72, issue.2, pp.478-485, 2016.

K. Champenois and J. Le-gall, ANRS-COM?TEST, La recherche communautaire VIH/sida, pp.327-342

D. W. Cockcroft and H. H. Gault, Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976.

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. (. Zhang, A. F. Castro et al., A New Equation to Estimate Glomerular Filtration Rate, Annals of Internal Medicine, vol.150, issue.9, p.604, 2009.

J. W. Rowe, R. Andres, J. D. Tobin, A. H. Norris, and N. W. Shock, The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study, Journal of Gerontology, vol.31, issue.2, pp.155-163, 1976.

. Kdigo and . Kdigo, Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 2018.

R. M. Grant, P. L. Anderson, V. Mcmahan, A. Liu, K. R. Amico et al., Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study, The Lancet Infectious Diseases, vol.14, issue.9, pp.820-829, 2014.

S. M. Vrouenraets, C. A. Fux, F. W. Wit, E. F. Garcia, H. Furrer et al., Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity, AIDS, vol.25, issue.17, pp.2149-2155, 2011.

T. Stehlé, M. Vignon, M. Flamant, M. Figueres, M. Rabant et al., Loss of tubular creatinine secretion as the only sign of tubular proximal cell dysfunction in light chain proximal tubulopathy, Medicine, vol.95, issue.26, p.e3815, 2016.

. Pre-exposure, Prophylaxis (PrEP) | HIV Risk and Prevention | HIV/AIDS | CDC, 2018.

J. Wittmann, « C?est poète que je veux être ! C?est poète que je suis ! ». La place paradoxale de la poésie dans la carrière littéraire de Gide, La poésie, entre vers et prose, pp.139-149

, 3.1.1. Emploi dans le secteur de la santé et des services sociaux en pourcentage de l'emploi civil total, 1995 et 2009 (ou année la plus proche)

. Prâevost, Â. M. Chomprâe, A. Deleyre, J. Green, A. Meusnier-de-querlon et al., Histoire gâenâerale des voyages, ou, Nouvelle collection de toutes les relations de voyages par mer et par terre, qui ont âetâe publiâees jusqu'áa present dans les diffâerentes langues de toutes les nations connues : contenant ce qu'il y a de plus remarquable, de plus utile et de mieux averâe dans les pays ou les voyageurs ont penetrâe : touchant leur situation, leur âetendue, leurs limites, leurs divisions, leur climat, leur terroir, leurs productions, leurs lacs, leurs rivieres, leurs montagnes, leurs mines, leurs citâes & leurs principales villes, leurs ports, leurs rades, leurs edifices, &c. : avec les moeurs et les usages des habitans, leur religion, leur gouvernement, leurs arts et leurs sciences, leur commerce et leurs manufactures : pour former un systâeme complet d'histoire et de gâeographie moderne, qui representera l'âetat actuel de toutes les nations : enrichi de cartes gâeographiques nouvellement composâees sur les observations les plus autentiques :, 1746.

, Comment puis-je me tenir informé des technologies les plus récentes, des nouveaux modèles de fabrication, et de la recherche-développement?, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences, 2003.

L. Madsen-brooks, « Je ne me suis pas perdue et ne souhaite pas que l?on me trouve ». Stratégies des femmes dans les musées de sciences en Californie (xixe-, Culture & musées, issue.30, pp.111-131, 2017.

M. Sandras, « Je ne suis pas un écrivain, je suis le poète qui chante » Les entretiens de Paul Fort avec Michel Manoll, Écrivains au micro, pp.201-15

M. Sandras, « Je ne suis pas un écrivain, je suis le poète qui chante » Les entretiens de Paul Fort avec Michel Manoll, Écrivains au micro, pp.201-15

A. Niess, Conclusion. Le spectre des deux-cents familles ?, L?hérédité en République, pp.327-328, 2012.

, Si je constate une violation de mes droits de propriété intellectuelle, que dois-je ou que puis-je faire?, 2004.